Drug Profile
Tregalizumab - Biotest
Alternative Names: Biotherapeutic agent BT-061 - Biotest AG; BT-061Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Biotest
- Developer Biotest AG; T-Balance Therapeutics
- Class Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Allergic asthma
- Preclinical Graft-versus-host disease
- Discontinued Multiple sclerosis; Plaque psoriasis; Rheumatoid arthritis
Most Recent Events
- 28 Nov 2022 Preclinical trials in Graft-versus-host disease in Germany (Parenteral) (T-Balance Therapeutics pipeline, November 2022)
- 28 Nov 2022 T-Balance Therapeutics plans a phase II clinical study in Graft-versus-host-disease (GvHD) (T-Balance Therapeutics pipeline, November 2022)
- 25 Apr 2022 Biotest AG has been acquired by Grifols